Etanercept

Drug Profile

Etanercept

Alternative Names: Enbrel; p75TNFR-Ig; rhu TNFR-Fc; Soluble tumour necrosis factor receptor p75 Fc IgG1 fusion protein; TNF receptor fusion protein; TNFR-Fc-p75; TNR-001

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Pantec Biosolutions; Pfizer; University of Leeds
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Phase III Graft-versus-host disease
  • Phase II Discoid lupus erythematosus
  • No development reported Metabolic syndrome
  • Discontinued Adult-onset Still's disease; Asthma; Behcet's syndrome; Cachexia; Heart failure; Myasthenia gravis; Pulmonary fibrosis; Septic shock; Transplant rejection; Wegener's granulomatosis

Most Recent Events

  • 28 Nov 2016 Phase-I clinical trials in Plaque psoriasis in Switzerland (Topical) (NCT02999776)
  • 04 Nov 2016 Registered for Plaque psoriasis (In adolescents, In children) in USA (SC)
  • 30 Sep 2016 The New Jersey District Court enters a preliminary injunction prohibiting Sandoz from making, using, importing, selling or offering for sale of Sandoz’s etanercept biosimilar for infringement of five patents (Amgen 10-Q, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top